Free tool
FAERS Monitor: Chlorhexidine Gluconate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021669 or its brand name (Chlorhexidine Gluconate, Chlorhexidine Gluconate). Reports on generic versions are filed under their own applications.
Reports
7,708
Serious
6,490
84% of reports
Hospitalization
3,781
Death reported
2,709
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue1,899
- joint swelling1,721
- rash1,692
- hypersensitivity1,663
- impaired healing1,631
- folliculitis1,619
- weight increased1,608
- pain1,585
- stomatitis1,569
- arthralgia1,554
- lower respiratory tract infection1,543
- glossodynia1,530
- blister1,515
- off label use1,512
- hand deformity1,506
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 19 |
| 2006 | 20 |
| 2007 | 38 |
| 2008 | 89 |
| 2009 | 95 |
| 2010 | 151 |
| 2011 | 160 |
| 2012 | 163 |
| 2013 | 64 |
| 2014 | 83 |
| 2015 | 131 |
| 2016 | 235 |
| 2017 | 267 |
| 2018 | 297 |
| 2019 | 309 |
| 2020 | 401 |
| 2021 | 676 |
| 2022 | 602 |
| 2023 | 506 |
| 2024 | 1,322 |
| 2025 | 1,535 |
| 2026 | 517 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,451 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| folliculitisSignal | 1,619 | 498.0 | 474.6 | 679,061 |
| hand deformitySignal | 1,506 | 353.8 | 336.9 | 468,970 |
| glossodyniaSignal | 1,530 | 200.1 | 190.9 | 282,515 |
| impaired healingSignal | 1,631 | 142.6 | 136.4 | 218,140 |
| lower respiratory tract infectionSignal | 1,543 | 95.8 | 91.5 | 140,058 |
| blisterSignal | 1,515 | 75.6 | 72.2 | 108,756 |
| stomatitisSignal | 1,569 | 72.4 | 69.3 | 107,919 |
| joint swellingSignal | 1,721 | 39.5 | 37.8 | 63,908 |
| hypersensitivitySignal | 1,663 | 24.7 | 23.6 | 37,719 |
| weight increasedSignal | 1,608 | 19.7 | 18.9 | 28,669 |
| rashSignal | 1,692 | 10.6 | 10.2 | 15,004 |
| arthralgiaSignal | 1,554 | 10.2 | 9.8 | 13,148 |
| painSignal | 1,585 | 7.1 | 6.8 | 8,459 |
| fatigueSignal | 1,899 | 6.7 | 6.4 | 9,475 |
| off label useSignal | 1,512 | 4.7 | 4.5 | 4,611 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.